Form 8-K Nurix Therapeutics, Inc. For: Jun 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Oppenheimer on Nurix (NRIX): 'A Big Check for a Big Opportunity'
June 8, 2026 10:48 AM EDTOppenheimer analyst Matthew Biegler reiterated an Outperform rating and $28.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Nurix announced a global collaboration with Roche to co-develop and co-commercialize bex-deg, and in our view this is the outcome investors were hoping... More
